DE60216952D1 - Beta-carbolin-derivate als ptp-inhibitoren - Google Patents

Beta-carbolin-derivate als ptp-inhibitoren

Info

Publication number
DE60216952D1
DE60216952D1 DE60216952T DE60216952T DE60216952D1 DE 60216952 D1 DE60216952 D1 DE 60216952D1 DE 60216952 T DE60216952 T DE 60216952T DE 60216952 T DE60216952 T DE 60216952T DE 60216952 D1 DE60216952 D1 DE 60216952D1
Authority
DE
Germany
Prior art keywords
diseases
inhibitors
ptpases
diabetes
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60216952T
Other languages
English (en)
Other versions
DE60216952T2 (de
Inventor
M Mjalli
C Andrews
Rongyuan Xie
R Yarragunta
Tan Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Application granted granted Critical
Publication of DE60216952D1 publication Critical patent/DE60216952D1/de
Publication of DE60216952T2 publication Critical patent/DE60216952T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60216952T 2001-10-19 2002-10-18 Beta-carbolin-derivate als ptp-inhibitoren Expired - Fee Related DE60216952T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34612501P 2001-10-19 2001-10-19
US34617601P 2001-10-19 2001-10-19
US346125P 2001-10-19
US346176P 2001-10-19
PCT/US2002/033520 WO2003033496A1 (en) 2001-10-19 2002-10-18 Beta-carbolin derivatives as ptp-inhibitors

Publications (2)

Publication Number Publication Date
DE60216952D1 true DE60216952D1 (de) 2007-02-01
DE60216952T2 DE60216952T2 (de) 2007-07-05

Family

ID=26994711

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60216952T Expired - Fee Related DE60216952T2 (de) 2001-10-19 2002-10-18 Beta-carbolin-derivate als ptp-inhibitoren

Country Status (9)

Country Link
US (2) US6933303B2 (de)
EP (1) EP1438310B1 (de)
JP (1) JP2005508968A (de)
AT (1) ATE348828T1 (de)
DE (1) DE60216952T2 (de)
DK (1) DK1438310T3 (de)
ES (1) ES2278064T3 (de)
HK (1) HK1067128A1 (de)
WO (1) WO2003033496A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
EP1590349A1 (de) 2003-01-27 2005-11-02 Pfizer Inc. Hiv-integrase-inhibitoren, pharmazeutische zusammensetzung, und verfahren zu deren anwendung
WO2004071448A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
EP1594847A2 (de) * 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituierte azolderivate zur therapeutischen verwendung
US7459472B2 (en) * 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
AU2004263508A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005035551A2 (en) 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2005063748A1 (en) * 2003-12-31 2005-07-14 Council Of Scientific And Industrial Research β-CARBOLINE DERIVED GUANIDINE ALKALOID, TIRUCHENDURAMINE
CN1910183A (zh) 2004-01-23 2007-02-07 希龙公司 四氢咔啉化合物作为抗癌药
CA2551909C (en) * 2004-02-12 2011-10-11 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
UA92317C2 (ru) * 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7626025B2 (en) 2004-03-30 2009-12-01 Council Of Scientific And Industrial Research Beta-carboline derived guanidine alkaloids, tiruchenduramine
BRPI0510319A (pt) 2004-04-26 2007-10-16 Pfizer inibidores da enzima integrase de hiv
EP1751157B1 (de) 2004-04-26 2007-10-03 Pfizer Inc. Inhibitoren des hiv-integrase-enzyms
CN1976930B (zh) * 2004-05-17 2011-01-19 泰博特克药品有限公司 用作抗感染药物的6,7,8,9-取代的1-苯基-1,5-二氢吡啶并(3,2-b)吲哚-2-酮
BRPI0511874A (pt) 2004-06-09 2008-01-15 Glaxo Group Ltd derivados da pirrolopiridina
EP1991544B1 (de) 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituierte imidazol- derivate und ihre verwendung als ptpase inhibitoren
EP2178537A4 (de) * 2007-07-19 2011-08-17 Merck Sharp & Dohme Beta-carbolin-derivate als antidiabetische verbindungen
WO2009118259A1 (en) * 2008-03-25 2009-10-01 Merck Serono S.A. Ptph1 inhibitors for the treatment of alzheimer's disease
MA33219B1 (fr) 2009-03-30 2012-04-02 Transtech Pharma Inc Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
TWI671297B (zh) 2009-05-27 2019-09-11 Ptc治療公司 治療癌症及非腫瘤病症之方法
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
CN102459263A (zh) 2009-05-27 2012-05-16 Ptc医疗公司 取代的四氢β-咔啉的制备工艺
US20100323979A1 (en) * 2009-06-16 2010-12-23 Weis-Amon Angelika B Methods and compositions for inhibiting proliferation of aneuploid cells
US9169247B2 (en) 2009-11-20 2015-10-27 Southern Research Institute Tetrahydro-beta-carboline derivatives, synthesis and use thereof
TW201309698A (zh) 2011-03-18 2013-03-01 Ono Pharmaceutical Co 四氫咔啉衍生物
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
CN103159758B (zh) * 2011-12-13 2015-08-05 首都医科大学 (1S,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸、其合成、抗栓活性和作为抗血栓剂的应用
US20150018369A1 (en) * 2012-01-09 2015-01-15 University Of Washington Through Its Center For Commercialization Compositions and Methods for Treating Malignant Astrocytomas
CN105153277A (zh) * 2014-06-11 2015-12-16 首都医科大学 KE修饰的β-咔啉,其制备,纳米结构,活性和应用
IL295050A (en) 2016-04-01 2022-09-01 Recurium Ip Holdings Llc Estrogen receptor modulators
US11289654B2 (en) 2016-12-22 2022-03-29 Guangzhou Chinaray Optoelectronic Materials Ltd. Polymers containing furanyl crosslinkable groups and uses thereof
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2019028171A1 (en) 2017-08-01 2019-02-07 Ptc Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤
EP4267578A1 (de) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Östrogenrezeptormodulatoren
WO2024039861A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244905A (en) * 1990-08-31 1993-09-14 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl polyhydro-β-carboline-phenylalanine- and phenethylamine derivatives
US5770620A (en) * 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
US6388076B1 (en) * 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
DK0891187T3 (da) * 1996-04-04 2002-04-29 Hoffmann La Roche Anvendelse af tetrahydro-beta-carbolin-derivater som antimetastatiske midler
AU8071698A (en) * 1997-06-13 1998-12-30 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
AU2713799A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)

Also Published As

Publication number Publication date
WO2003033496A1 (en) 2003-04-24
US20050096335A1 (en) 2005-05-05
EP1438310A1 (de) 2004-07-21
US6933303B2 (en) 2005-08-23
US20040014778A1 (en) 2004-01-22
HK1067128A1 (en) 2005-04-01
DE60216952T2 (de) 2007-07-05
ATE348828T1 (de) 2007-01-15
EP1438310B1 (de) 2006-12-20
DK1438310T3 (da) 2007-03-26
ES2278064T3 (es) 2007-08-01
JP2005508968A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
DE60216952D1 (de) Beta-carbolin-derivate als ptp-inhibitoren
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
AU2003282234A1 (en) Benzofuran derivates, process for their preparation and intermediates thereof
RS20050363A (en) Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
WO2004071448A3 (en) Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
AU2003209118A1 (en) Aryl ureas as kinase inhibitors
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
MXPA03006749A (es) Proceso para la sintesis de compuestos de urea sustituidos con heteroarilo, utiles como agentes antiinflamatorios.
SG149045A1 (en) Novel fused pyrrolocarbazoles
SG149042A1 (en) Novel fused pyrrolocarbazoles
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
AU2003260436A1 (en) Pyrimidine compounds
DE602004007672D1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
EP1812007A4 (de) Pyridazinverbindungen und verfahren
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
DK1441724T3 (da) Fremgangsmåde til forögelse af endogene testosteronniveauer
BRPI0415355A (pt) triarilimidazóis
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee